Shu Mei Kato

Title(s)Associate Clinical Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Overview 
    Collapse Websites

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Multi-omic analysis in carcinoma of unknown primary (CUP): therapeutic impact of knowing the unknown. Mol Oncol. 2022 Jul 22. Kato S, Gumas S, Adashek JJ, Okamura R, Lee S, Sicklick JK, Kurzrock R. PMID: 35866362.
      View in: PubMed   Mentions: 5     Fields:    
    2. Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience. Mol Oncol. 2022 07; 16(13):2575-2584. Louie BH, Kato S, Kim KH, Lim HJ, Lee S, Okamura R, Fanta PT, Kurzrock R. PMID: 35238467; PMCID: PMC9251876.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    3. Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting. Oncoimmunology. 2022; 11(1):2052410. Kato S, Li B, Adashek JJ, Cha SW, Bianchi-Frias D, Qian D, Kim L, So TW, Mitchell M, Kamei N, Hoiness R, Hoo J, Gray PN, Iyama T, Kashiwagi M, Lu HM, Kurzrock R. PMID: 35371621; PMCID: PMC8966985.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    4. Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies. NPJ Precis Oncol. 2022 Mar 28; 6(1):18. Gupta D, Kurzrock R, Lee S, Okamura R, Lim HJ, Kim KH, Sicklick JK, Kato S. PMID: 35347205; PMCID: PMC8960821.
      View in: PubMed   Mentions: 1  
    5. Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine. JCO Precis Oncol. 2022 01; 6:e2000508. Charo LM, Eskander RN, Sicklick J, Kim KH, Lim HJ, Okamura R, Lee S, Subramanian R, Schwab R, Shatsky R, Plaxe S, Kato S, Kurzrock R. PMID: 35005995; PMCID: PMC8769125.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    6. Cetuximab in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Alterations. Clin Oncol Case Rep. 2022 Jan; 5(1). Nikanjam M, Kato S, Adashek JJ, Kurzrock R. PMID: 35403176; PMCID: PMC8994415.
      View in: PubMed   Mentions: 1  
    7. Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary. JCO Precis Oncol. 2021; 5. Kato S, Weipert C, Gumas S, Okamura R, Lee S, Sicklick JK, Saam J, Kurzrock R. PMID: 34778692; PMCID: PMC8585281.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    8. Hyperprogression in Gastric Cancer: Is MDM2 Amplification the Dark Horse? JCO Precis Oncol. 2021 11; 5:931-932. Dayyani F, Kato S, Kurzrock R. PMID: 34994620.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Palbociclib as a Novel Therapy for Low-Grade Mucinous Carcinomatosis Peritonei of Appendiceal Origin. JCO Precis Oncol. 2021 11; 5:1069-1072. Childers BG, Sood D, Patel R, Mose ES, Hosseini M, Kato S, Baumgartner JM, Lowy AM. PMID: 34994628.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy. Mol Cancer Ther. 2021 12; 20(12):2341-2351. Mardinian K, Adashek JJ, Botta GP, Kato S, Kurzrock R. PMID: 34642211; PMCID: PMC8643328.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    11. Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. Genome Med. 2021 10 04; 13(1):155. Sicklick JK, Kato S, Okamura R, Patel H, Nikanjam M, Fanta PT, Hahn ME, De P, Williams C, Guido J, Solomon BM, McKay RR, Krie A, Boles SG, Ross JS, Lee JJ, Leyland-Jones B, Lippman SM, Kurzrock R. PMID: 34607609; PMCID: PMC8491393.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    12. Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity. Clin Cancer Res. 2021 10 01; 27(19):5334-5342. Sharma AK, de la Torre J, IJzerman NS, Sutton TL, Zhao B, Khan TM, Banerjee S, Cui C, Nguyen V, Alkhuziem M, Snaebjornsson P, van Boven H, Bruining A, Tang CM, Yoon H, De la Fuente A, Kato S, Patel H, Heinrich MC, Corless CL, Horgan S, Burgoyne AM, Fanta P, Mesirov JP, Blakely AM, Davis JL, Mayo SC, van Houdt WJ, Steeghs N, Sicklick JK. PMID: 34326133; PMCID: PMC8799780.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    13. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. JCI Insight. 2021 09 22; 6(18). Botta GP, Kato S, Patel H, Fanta P, Lee S, Okamura R, Kurzrock R. PMID: 34375311; PMCID: PMC8492298.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    14. Targeting ARID1A mutations in cancer. Cancer Treat Rev. 2021 Nov; 100:102287. Mullen J, Kato S, Sicklick JK, Kurzrock R. PMID: 34619527.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimals
    15. A phase i study of ixazomib and erlotinib in patients with advanced solid tumors. Invest New Drugs. 2022 02; 40(1):99-105. Kato S, Adashek JJ, Subbiah V, Fu S, Sun M, Nguyen L, Brown EJ, Yap TA, Karp DD, Piha-Paul SA, Hong DS. PMID: 34468905.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    16. Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible. Mol Cancer Ther. 2021 11; 20(11):2274-2279. Jensen TJ, Goodman AM, Ellison CK, Holden KA, Kato S, Kim L, Daniels GA, Fitzgerald K, McCarthy E, Nakashe P, Mazloom AR, Almasri E, McLennan G, Grosu DS, Eisenberg M, Kurzrock R. PMID: 34465593.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    17. Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns. Oncologist. 2021 09; 26(9):787-796. Israel MA, Danziger N, McGregor KA, Murugesan K, Gjoerup O, Sokol ES, Tukachinsky H, Kurzrock R, Kato S, Sicklick JK, Nimeiri HS, Oxnard GR, Ross JS. PMID: 34080753; PMCID: PMC8417854.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    18. Did Everolimus Break the Rules? Clin Cancer Res. 2021 07 15; 27(14):3807-3808. Kato S, Cohen EEW. PMID: 33986025.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation. Oncologist. 2021 07; 26(7):e1104-e1109. Kim JW, Cardin DB, Vaishampayan UN, Kato S, Grossman SR, Glazer PM, Shyr Y, Ivy SP, LoRusso PM. PMID: 33742489; PMCID: PMC8265343.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    20. Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021 May; 18(5):320. Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working Group. PMID: 33758378; PMCID: PMC7985918.
      View in: PubMed   Mentions: 3     Fields:    
    21. Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors. Eur J Cancer. 2021 05; 149:184-192. Kato S, Porter R, Okamura R, Lee S, Zelichov O, Tarcic G, Vidne M, Kurzrock R. PMID: 33865203.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    22. Missing the target in cancer therapy. Nat Cancer. 2021 04; 2:369-371. Adashek JJ, Goloubev A, Kato S, Kurzrock R. PMID: 34368781; PMCID: PMC8336921.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    23. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021 05; 18(5):313-319. Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working Group. PMID: 33723371; PMCID: PMC7957448.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCellsPHPublic Health
    24. KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery. Oncologist. 2021 04; 26(4):e530-e536. Kato S, McFall T, Takahashi K, Bamel K, Ikeda S, Eskander RN, Plaxe S, Parker B, Stites E, Kurzrock R. PMID: 33528846; PMCID: PMC8018312.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    25. High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment. Int J Cancer. 2021 06 01; 148(11):2839-2847. Okamura R, Piccioni DE, Boichard A, Lee S, Jimenez RE, Sicklick JK, Kato S, Kurzrock R. PMID: 33497479; PMCID: PMC8048515.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    26. Cancer of Unknown Primary in the Molecular Era. Trends Cancer. 2021 05; 7(5):465-477. Kato S, Alsafar A, Walavalkar V, Hainsworth J, Kurzrock R. PMID: 33516660; PMCID: PMC8062281.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    27. Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics. Clin Cancer Res. 2021 05 15; 27(10):2792-2797. Kato S, Adashek JJ, Shaya J, Okamura R, Jimenez RE, Lee S, Sicklick JK, Kurzrock R. PMID: 33472910.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    28. Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens. JCI Insight. 2021 01 11; 6(1). Kato S, Okamura R, Adashek JJ, Khalid N, Lee S, Nguyen V, Sicklick JK, Kurzrock R. PMID: 33427211; PMCID: PMC7821594.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    29. Immune profiling and immunotherapeutic targets in pancreatic cancer. Ann Transl Med. 2021 Jan; 9(2):119. Lenzo FL, Kato S, Pabla S, DePietro P, Nesline MK, Conroy JM, Burgher B, Glenn ST, Kuvshinoff B, Kurzrock R, Morrison C. PMID: 33569421; PMCID: PMC7867882.
      View in: PubMed   Mentions: 9  
    30. The Impact of COVID-19 on Cancer Clinical Trials Conducted by NCI-Designated Comprehensive Cancer Centers. J Immunother Precis Oncol. 2021 May; 4(2):56-63. Gupta D, Kato S, Kurzrock R. PMID: 34337550; PMCID: PMC8320380.
      View in: PubMed   Mentions: 5  
    31. Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. Cancer. 2021 02 01; 127(3):391-402. Janku F, Sakamuri D, Kato S, Huang HJ, Call SG, Naing A, Holley VR, Patel SP, Amaria RN, Falchook GS, Piha-Paul SA, Zinner RG, Tsimberidou AM, Hong DS, Meric-Bernstam F. PMID: 33119140.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    32. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020 10 02; 11(1):4965. Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R. PMID: 33009371; PMCID: PMC7532150.
      View in: PubMed   Mentions: 103     Fields:    Translation:Humans
    33. Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience. Oncologist. 2020 11; 25(11):e1803-e1806. Bohan SS, Sicklick JK, Kato S, Okamura R, Miller VA, Leyland-Jones B, Lippman SM, Kurzrock R. PMID: 32949172; PMCID: PMC7648352.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    34. Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA TP53 Mutations-A Perspective from a Real-World Precision Medicine Cohort. Mol Cancer Ther. 2020 12; 19(12):2612-2620. Rosenberg S, Okamura R, Kato S, Soussi T, Kurzrock R. PMID: 32999047.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    35. Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. Mol Oncol. 2021 01; 15(1):67-79. Charo LM, Eskander RN, Okamura R, Patel SP, Nikanjam M, Lanman RB, Piccioni DE, Kato S, McHale MT, Kurzrock R. PMID: 32881280; PMCID: PMC7782073.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    36. Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. Int J Cancer. 2021 02 01; 148(3):702-712. Okamura R, Kurzrock R, Mallory RJ, Fanta PT, Burgoyne AM, Clary BM, Kato S, Sicklick JK. PMID: 32700810; PMCID: PMC7739197.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    37. Letter responds to comment on "intention-to-treat analysis in precision oncology: A cautious interpretation". Eur J Cancer. 2020 10; 138:228. Sicklick J, Kato S, Kurzrock R. PMID: 32839070.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer. Front Oncol. 2020; 10:1312. Adashek JJ, Arroyo-Martinez Y, Menta AK, Kurzrock R, Kato S. PMID: 32850413; PMCID: PMC7418523.
      View in: PubMed   Mentions: 9  
    39. High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers. Mol Cancer Ther. 2020 10; 19(10):2139-2145. Riviere P, Goodman AM, Okamura R, Barkauskas DA, Whitchurch TJ, Lee S, Khalid N, Collier R, Mareboina M, Frampton GM, Fabrizio D, Sharabi AB, Kato S, Kurzrock R. PMID: 32747422; PMCID: PMC7541603.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    40. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy. Cureus. 2020 Jul 02; 12(7):e8967. Cohen PR, Nikanjam M, Kato S, Goodman AM, Kurzrock R. PMID: 32766009; PMCID: PMC7398726.
      View in: PubMed   Mentions: 1  
    41. Transcriptomic silencing as a potential mechanism of treatment resistance. JCI Insight. 2020 06 04; 5(11). Adashek JJ, Kato S, Parulkar R, Szeto CW, Sanborn JZ, Vaske CJ, Benz SC, Reddy SK, Kurzrock R. PMID: 32493840; PMCID: PMC7308055.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    42. Repurposing Interleukin-6 Inhibitors to Combat COVID-19. J Immunother Precis Oncol. 2020; 3(2):52-55. Kato S, Kurzrock R. PMID: 34169296; PMCID: PMC8221576.
      View in: PubMed   Mentions: 6  
    43. MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Med. 2020 05 19; 12(1):45. Goodman AM, Castro A, Pyke RM, Okamura R, Kato S, Riviere P, Frampton G, Sokol E, Zhang X, Ball ED, Carter H, Kurzrock R. PMID: 32430031; PMCID: PMC7236948.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    44. Precision oncology: the intention-to-treat analysis fallacy. Eur J Cancer. 2020 07; 133:25-28. Sicklick JK, Kato S, Okamura R, Kurzrock R. PMID: 32422506; PMCID: PMC7786388.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    45. The paradox of cancer genes in non-malignant conditions: implications for precision medicine. Genome Med. 2020 02 17; 12(1):16. Adashek JJ, Kato S, Lippman SM, Kurzrock R. PMID: 32066498; PMCID: PMC7027240.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    46. ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. J Immunother Cancer. 2020 02; 8(1). Okamura R, Kato S, Lee S, Jimenez RE, Sicklick JK, Kurzrock R. PMID: 32111729; PMCID: PMC7057434.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    47. Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. Int J Cancer. 2020 06 15; 146(12):3450-3460. Kato S, Okamura R, Sicklick JK, Daniels GA, Hong DS, Goodman A, Weihe E, Lee S, Khalid N, Collier R, Mareboina M, Riviere P, Whitchurch TJ, Fanta PT, Lippman SM, Kurzrock R. PMID: 31782524; PMCID: PMC10200262.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    48. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol. 2019 12 04; 12(1):130. Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R. PMID: 31801585; PMCID: PMC6894333.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    49. Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? Oncologist. 2020 02; 25(2):94-98. Adashek JJ, Kato S, Ferrara R, Lo Russo G, Kurzrock R. PMID: 32043794; PMCID: PMC7011624.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    50. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. Mol Cancer Ther. 2019 10; 18(10):1852-1862. Choi IS, Kato S, Fanta PT, Leichman L, Okamura R, Raymond VM, Lanman RB, Lippman SM, Kurzrock R. PMID: 31320401.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    51. Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting. Int J Cancer. 2020 01 15; 146(2):566-576. Mardinian K, Okamura R, Kato S, Kurzrock R. PMID: 31199507; PMCID: PMC6874714.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    52. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Mol Cancer Ther. 2019 06; 18(6):1149-1157. Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R. PMID: 31015311; PMCID: PMC6548628.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    53. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019 05; 25(5):744-750. Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R. PMID: 31011206; PMCID: PMC6553618.
      View in: PubMed   Mentions: 247     Fields:    Translation:HumansCTClinical Trials
    54. Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. Cancer Immunol Res. 2019 06; 7(6):866-873. Goodman AM, Kato S, Chattopadhyay R, Okamura R, Saunders IM, Montesion M, Frampton GM, Miller VA, Daniels GA, Kurzrock R. PMID: 31003990; PMCID: PMC6548620.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    55. Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. JCO Precis Oncol. 2019; 3. Kato S, Schwaederlé MC, Fanta PT, Okamura R, Leichman L, Lippman SM, Lanman RB, Raymond VM, Talasaz A, Kurzrock R. PMID: 31032472; PMCID: PMC6484865.
      View in: PubMed   Mentions: 30     Fields:    
    56. Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. JCO Precis Oncol. 2019; 3. Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R. PMID: 31058253; PMCID: PMC6497417.
      View in: PubMed   Mentions: 37     Fields:    
    57. Identification of targets for prostate cancer immunotherapy. Prostate. 2019 04; 79(5):498-505. Papanicolau-Sengos A, Yang Y, Pabla S, Lenzo FL, Kato S, Kurzrock R, DePietro P, Nesline M, Conroy J, Glenn S, Chatta G, Morrison C. PMID: 30614027.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    58. Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients. Mol Cancer Ther. 2019 02; 18(2):448-458. Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, Nakashe P, McCarthy E, Mazloom AR, McLennan G, Grosu DS, Ehrich M, Kurzrock R. PMID: 30523049.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    59. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol. 2018; 2018. Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. PMID: 30637364; PMCID: PMC6329466.
      View in: PubMed   Mentions: 120     Fields:    
    60. An avatar for precision cancer therapy. Nat Biotechnol. 2018 11 09; 36(11):1053-1055. Kato S, Kurzrock R. PMID: 30412185.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    61. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472. Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. PMID: 30383888; PMCID: PMC6340722.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    62. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. Clin Cancer Res. 2018 12 15; 24(24):6248-6256. Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, Sicklick JK, Fanta PT, Lippman SM, Kurzrock R. PMID: 30348637; PMCID: PMC6384095.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    63. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA Oncol. 2018 09 01; 4(9):1237-1244. Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R. PMID: 29902298; PMCID: PMC6139049.
      View in: PubMed   Mentions: 133     Fields:    Translation:Humans
    64. JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. Cancer Biol Ther. 2018 08 03; 19(8):664-668. Choi MY, Kato S, Wang HY, Lin JH, Lanman RB, Kurzrock R. PMID: 29565699; PMCID: PMC6067874.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    65. Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. JCO Precis Oncol. 2018; 2018. Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, Kurzrock R. PMID: 30148248; PMCID: PMC6106866.
      View in: PubMed   Mentions: 32     Fields:    
    66. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer. 2018 05; 118(11):1419-1424. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. PMID: 29695765; PMCID: PMC5988803.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    67. Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of Disease. Oncology (Williston Park). 2018 04 15; 32(4):150-1, 163. Kurzrock R, Kato S. PMID: 29684227.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    68. Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies. Oncoimmunology. 2018; 7(3):e1404217. Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 29399405; PMCID: PMC5790366.
      View in: PubMed   Mentions: 29     Fields:    
    69. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs. 2018 06; 36(3):416-423. Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, Urban S, Browne E, Meric-Bernstam F, Hong DS. PMID: 29047029; PMCID: PMC5908757.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    70. Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach. Oncologist. 2018 02; 23(2):171-178. Kato S, Kurasaki K, Ikeda S, Kurzrock R. PMID: 29038235; PMCID: PMC5813742.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    71. Genomics of Immunotherapy-Associated Hyperprogressors-Response. Clin Cancer Res. 2017 10 15; 23(20):6376. Kato S, Kurzrock R. PMID: 29030333.
      View in: PubMed   Mentions: 6     Fields:    
    72. Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. Cancer Discov. 2017 12; 7(12):1464-1479. Seguin L, Camargo MF, Wettersten HI, Kato S, Desgrosellier JS, von Schalscha T, Elliott KC, Cosset E, Lesperance J, Weis SM, Cheresh DA. PMID: 28893801; PMCID: PMC5718959.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimalsCells
    73. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017 11; 16(11):2598-2608. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 28835386; PMCID: PMC5670009.
      View in: PubMed   Mentions: 1096     Fields:    Translation:HumansAnimalsCells
    74. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. Cancer Res. 2017 10 01; 77(19):5419-5427. Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R. PMID: 28807936; PMCID: PMC5626633.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    75. Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease. Int J Mol Sci. 2017 Jul 31; 18(8). Cohen PR, Kato S, Goodman AM, Ikeda S, Kurzrock R. PMID: 28788102; PMCID: PMC5578053.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    76. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res. 2017 Aug 01; 23(15):4155-4162. Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS. PMID: 28729355; PMCID: PMC5902668.
      View in: PubMed   Mentions: 2     Fields:    
    77. Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit. J Natl Compr Canc Netw. 2017 07; 15(7):863-866. Kato S, Subbiah V, Kurzrock R. PMID: 28687573; PMCID: PMC6317845.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    78. Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. Cancer Res. 2017 08 15; 77(16):4238-4246. Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman SM, Lanman RB, Kurzrock R. PMID: 28642281; PMCID: PMC5729906.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    79. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. Oncologist. 2017 06; 22(6):631-637. Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, Weihe E, Kurzrock R. PMID: 28550027; PMCID: PMC5469598.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    80. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res. 2017 Aug 01; 23(15):4242-4250. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. PMID: 28351930; PMCID: PMC5647162.
      View in: PubMed   Mentions: 438     Fields:    Translation:Humans
    81. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res. 2017 04 15; 23(8):1988-1997. Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. PMID: 27683183.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    82. Genomic Landscape of Malignant Mesotheliomas. Mol Cancer Ther. 2016 10; 15(10):2498-2507. Kato S, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R. PMID: 27507853.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    83. Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 07; 15(7):1682-90. Helsten T, Kato S, Schwaederle M, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R. PMID: 27196769.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    84. The Conundrum of Genetic "Drivers" in Benign Conditions. J Natl Cancer Inst. 2016 08; 108(8). Kato S, Lippman SM, Flaherty KT, Kurzrock R. PMID: 27059373; PMCID: PMC5017937.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    85. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine. Oncotarget. 2015 Dec 01; 6(38):40642-54. Subbiah V, Wagner MJ, McGuire MF, Sarwari NM, Devarajan E, Lewis VO, Westin S, Kato S, Brown RE, Anderson P. PMID: 26510912; PMCID: PMC4747358.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    86. Genomic landscape of salivary gland tumors. Oncotarget. 2015 Sep 22; 6(28):25631-45. Kato S, Elkin SK, Schwaederle M, Tomson BN, Helsten T, Carter JL, Kurzrock R. PMID: 26247885; PMCID: PMC4694855.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    87. A window-of-opportunity biomarker study of etodolac in resectable breast cancer. Cancer Med. 2015 Oct; 4(10):1583-8. Schwab RB, Kato S, Crain B, Pu M, Messer K, Weidner N, Blair SL, Wallace AM, Carson DA, Parker BA. PMID: 26275572; PMCID: PMC4618628.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    88. Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients. Oncoscience. 2015; 2(7):646-58. Subbiah V, Bupathi M, Kato S, Livingston A, Slopis J, Anderson PM, Hong DS. PMID: 26328274; PMCID: PMC4549362.
      View in: PubMed   Mentions: 4  
    89. Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience. 2015; 2(6):576-80. Kato S, Moulder SL, Ueno NT, Wheler JJ, Meric-Bernstam F, Kurzrock R, Janku F. PMID: 26244164; PMCID: PMC4506360.
      View in: PubMed   Mentions: 15  
    90. Cell-free DNA as a novel marker in cancer therapy. Biomark Med. 2015; 9(7):703-12. Kato S, Janku F. PMID: 26174844.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    91. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. Cell Cycle. 2015; 14(8):1252-9. Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R. PMID: 25695927; PMCID: PMC4614867.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    92. Integrin αvβ3 drives slug activation and stemness in the pregnant and neoplastic mammary gland. Dev Cell. 2014 Aug 11; 30(3):295-308. Desgrosellier JS, Lesperance J, Seguin L, Gozo M, Kato S, Franovic A, Yebra M, Shattil SJ, Cheresh DA. PMID: 25117682; PMCID: PMC4147869.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimalsCells
    93. An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014 May; 16(5):457-68. Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM, Cheresh DA. PMID: 24747441; PMCID: PMC4105198.
      View in: PubMed   Mentions: 209     Fields:    Translation:HumansAnimalsCells
    94. EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1. PLoS One. 2012; 7(5):e36753. Lau SK, Shields DJ, Murphy EA, Desgrosellier JS, Anand S, Huang M, Kato S, Lim ST, Weis SM, Stupack DG, Schlaepfer DD, Cheresh DA. PMID: 22586492; PMCID: PMC3346745.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    See more options in the Advanced Search tab

    Shu Mei's Networks
    Concepts (289)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (60)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California